Page URL: https://www.bionews.org.uk/page_92492

First clinical trial of human embryonic stem cells gets go-ahead

2 August 2010
Appeared in BioNews 569

Biotechnology Company Geron has been given the all clear for the world's first clinical trial involving human embryonic stem cells (hESCs). This comes a year after the US Food and Drug Administration (FDA) placed the study on hold amid safety fears.

The Phase I trial will use stem cells derived from human embryos to attempt to regenerate neural support tissue in patients with severe spinal cord injury. Geron are hopeful this could restore some sensation and movement in patients.

The treatment, called GRNOPC1, was initially given the go-ahead by the FDA back in January 2009. The following August however, the FDA banned the trial after the appearance of cysts in some of the animals given the treatment in a preliminary study.

During the last year, Geron have developed new markers and assays, which improve the guidelines for treatment. On completing a confirmatory preclinical trial in animals using the new markers and assays, Geron submitted the results to the FDA and the hold on the human study was lifted on July 30th.

Geron's president and CEO, Dr Okarma, said: 'Our goals for the application of GRNOPC1 in sub-acute spinal cord injury are unchanged - to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord'.

The primary aim of the Phase I trial is to assess safety of the treatment in human patients, although Geron will also be assessing how well the treatment improves muscle function and feeling in the patients' upper body or lower extremities.

'We are pleased with the FDA's decision to allow our planned clinical trial of GRNOPC1 in spinal cord injury to proceed', said Dr Okarma. 'Additionally, we are now formally exploring the utility of GRNOPC1 in other degenerative CNS (central nervous system) disorders including Alzheimer's, multiple sclerosis, and Canavan disease'.

SOURCES & REFERENCES
Embryonic stem cell trial back on
The Scientist |  30 July 2010
FDA Clears Geron to Start World’s First Trial with hESC Therapy
GEN |  30 July 2010
Geron rallies as FDA green lights stem cell study
MarketWatch |  30 July 2010
Geron Rallies As FDA Lifts Hold On Stem-Cell Therapy
WSJ |  30 July 2010
Geron stem cell trial for spinal cord injury gets FDA approval
San Jose Business Journal |  30 July 2010
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
22 October 2012 - by Dr Anna Cauldwell 
Two former CEOs of US drug company Geron are bidding to revive its stem cell assets...
31 May 2011 - by Dr Kimberley Bryon-Dodd 
Two genetic regions that might explain some differences in disease severity in cystic fibrosis (CF) patients have been identified by US and Canadian researchers. The two regions contain genes that can modify lung function...
13 December 2010 - by Chris Chatterton 
Preliminary findings from a new research study have helped give scientists a new insight into how the body naturally repairs myelin, the substance that insulates nerve cells in the brain...
23 November 2009 - by Alison Cranage 
Stem cell therapy came one step closer to being tested for the first time in people this week, as a US company applied to the Food and Drug Administration (FDA) for a licence to start a clinical trial. The embryonic stem (ES) cell therapy is being developed to treat Stargardt, a currently incurable disease that causes blindness in young people....
8 November 2009 - by Dr Jay Stone 
American company Geron Corporation (GC) has been given permission to resume its clinical trials testing the embryonic stem cell treatment GRNPOC1....
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.